Synthesis 1996; 1996(11): 1325-1330
DOI: 10.1055/s-1996-4383
paper
© Georg Thieme Verlag, Rüdigerstr. 14, 70469 Stuttgart, Germany. All rights reserved. This journal, including all individual contributions and illustrations published therein, is legally protected by copyright for the duration of the copyright period. Any use, exploitation or commercialization outside the narrow limits set by copyright legislation, without the publisher's consent, is illegal and liable to criminal prosecution. This applies in particular to photostat reproduction, copying, cyclostyling, mimeographing or duplication of any kind, translating, preparation of microfilms, and electronic data processing and storage.

Synthesis of the Imidazole-Derived AT1-Selective ANG II Receptor Antagonist HR 720 Utilizing Reductive Amination as Key Step

Holger Heitsch1 , Adalbert Wagner, Neerja Yadav-Bhatnagar2 , Christine Griffoul-Marteau
  • 1HOECHST AG, HMR TA Cardiovascular Agents, G 838, D-65926 Frankfurt/Main, Germany, Fax +49(69)30581551; E-mail heitsch@msmrd.frankfurt.hoechst-ag.d400.de
  • 2ROUSSEL UCLAF, 102 Route de Noissy, F-93235 Romainville Cedex, France
Further Information

Publication History

Publication Date:
31 December 2000 (online)

The straightforward synthesis of the (1-methylbiphenylsulfonyl)-urea substituted imidazole HR 720, an orally active ANG II receptor antagonist, by reductive amination of 2’-sulfonamidobiphenylcarbaldehydes, derived from Suzuki-type phenyl-phenyl coupling procedures, as key step is described.

    >